Biotech Bonanza – Insider Weekends

Avadel Pharmaceuticals (AVDL): $7.75

Market Cap: $746.8M

Enterprise Value: $720.16M

Key Insights:

• We decided to look beyond our top insider purchases and sales this week and write about Avadel Pharmaceuticals, a small-cap biotech that focuses on treating narcolepsy.
• Avadel and the FDA were sued by the biotech giant Jazz Pharmaceuticals, which claimed that Avadel’s narcolepsy-treating drug, Lumryz, violated the exclusivity given to Jazz Pharmaceuticals’ narcolepsy drug Xywav.
• The key difference between Lumryz and Xywav is that Lumryz is a single-dosage once-at-bedtime drug, whereas Xywav is a split-dose drug that requires users to wake up for a second dose.

Only plus or premium subscribers can access this post. Subscribe today.